News
-
-
-
COMMUNIQUÉ DE PRESSE
As the Ebola Epidemic Spreads, NanoViricides Advances Towards a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo
NanoViricides, Inc. updates advancement of NV-387 broad-spectrum antiviral drug towards Phase II Clinical Trial for Bundibugyo Ebolavirus treatment in the DRC amid expanding outbreak. An oral gummies formulation has potential against Ebola viruses -
-
-
COMMUNIQUÉ DE PRESSE
US FDA Has Granted A "Rare Pediatric Disease Drug" Designation for NV-387 As A Treatment for Measles - Enables Priority Review Voucher
NanoViricides, Inc. receives Rare Pediatric Disease Drug (RPDD) Designation from US FDA for antiviral drug NV-387 for Measles treatment, offering potential Priority Review Voucher benefits. Drug shows promise against rising Measles cases globally -
-
-
-
